Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
IHL-42X screening begins as Incannex Healthcare enters a faster-moving oral sleep apnea race
Incannex Healthcare begins IHL-42X screening as cash, buybacks and Apnimed’s FDA filing reshape the oral sleep apnea investment case.
Neuphoria Therapeutics shares jumped while Scancell plunged, and the merger terms explain why
Scancell’s Neuphoria Therapeutics merger unlocks Nasdaq access and up to $89 million, but dilution and debt reshape the iSCIB1+ outlook.
Furoscix ReadyFlow approval triggers $45m bill as MannKind Corporation raises fresh capital
MannKind Corporation wins Furoscix ReadyFlow approval and raises $50 million as a $45 million acquisition payment reshapes the outlook.
IKT-001 gains orphan status, but Inhibikase Therapeutics still faces imatinib’s safety challenge
Inhibikase Therapeutics gains FDA orphan status for IKT-001 after a $50 million raise. See how trial costs and dilution shape the outlook.
Nuvectis Pharma’s ciprocopan approval validates its Haisco deal but raises the execution stakes
Nuvectis Pharma gains ciprocopan validation in China, but licensing costs, dilution and ex-China execution will determine its real value.
Wall Street welcomes Repligen’s $1.5bn BioLife deal, but integration now matters
Repligen’s $1.5bn BioLife deal targets recurring cell therapy revenue. See why investors welcomed the bet and where execution risk remains.
One leadership change, several major catalysts: What Vir Biotechnology must prove next
Vir Biotechnology’s finance leadership change comes as the biotechnology company manages more than $1 billion of financial resources, an important Astellas Pharma alliance and several potentially valuation-shaping clinical milestones.
GE HealthCare’s CFO is leaving with the stock near its yearly low. What happens next?
GE HealthCare Technologies has named George Newcomb interim finance chief after Jay Saccaro’s resignation, combining an unexpected leadership transition with stronger preliminary second-quarter results and reaffirmed 2026 guidance.
Scribe Therapeutics IPO raises $128.7m as CRISPR biotech prepares to trade as SCTX
Scribe Therapeutics expanded the offering by 20% and priced shares at the top of its range, strengthening its balance sheet before crucial STX-1150 human data expected in 2027.
Could D-PLEX100 turn surgical infection prevention into a breakout story for PolyPid?
PolyPid’s Azurity deal gives D-PLEX100 a U.S. and Canada launch path, with PYPD investors watching FDA acceptance and 2027 approval timing.